ZAKLADY FARMACEUTYCZNE POLPHARMA SA Patent applications |
Patent application number | Title | Published |
20120116092 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(1H-IMIDAZOL-1-YL)- ETHYLIDENE] BISPHOSPHONIC ACID - A process for the preparation of [1-hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid consists of the reaction of aqueous solution of 1H-imidazole-1-acetic acid hydrochloride with phosphorus trichloride followed by removal of the excess of phosphorus trichloride, addition of water and hydrolysis of the reaction products. In order to isolate the product the post-reaction mixture is filtered and the anti-solvent is added to the aqueous filtrate in order to crystallize out [1-hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid monohydrate. | 05-10-2012 |
20110065922 | Process for Preparation Of Solifenacin and/or the Pharmaceutically Acceptable Salts Thereof of High Pharmaceutical Purity - A process for the preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity is characterized in that 3-(R)-quinuclidinoloxy anion generated in situ from 3-(R)-quinuclidinol in a presence of strong base in polar organic solvent is subject to acylation with (S)-1-phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98%, while maintaining constant anion excess in a reaction mixture, and after reaction completion solifenacin base is optionally transformed into solifenacin salt according to standard procedures. (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98% is obtained in a reaction of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline and molar excess of phosgene in a presence of tertiary aromatic amine in aromatic hydrocarbon, and isolated in a crystalline form. | 03-17-2011 |
20110045085 | PROCESS FOR OBTAINING POWDER COMPOSITIONS OF ORLISTAT - The invention relates to a novel process for the manufacture of stable, meeting relevant quality requirements pharmaceutical compositions in the form of encapsulated powder comprising Orlistat and pharmaceutically acceptable additives. The invention further relates to pharmaceutical compositions of Orlistat in the form of encapsulated powder obtained in accordance with the process of the present invention. | 02-24-2011 |
20100255105 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING METOPROLOL SUCCINATE - An extended release pharmaceutical composition comprising metoprolol succinate and at least two pharmaceutically acceptable excipients, wherein the first pharmaceutically acceptable excipient is an extended release agent; the second pharmaceutically acceptable excipient is selected from a binder, a diluent and mixtures thereof; and metoprolol succinate is in a crystalline form having a D50 ranging from 5 to 16 microns and a D90 below 50 microns. | 10-07-2010 |
20100069641 | PROCESS FOR THE PREPARATION OF SODIUM SALT OF 1-(((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(1-HYDROXY-1- -METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID - A novel process for the preparation of a sodium salt of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methyl-ethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid, comprising: a) reacting a compound of Formula 1 with methanesulfonyl chloride in the presence of a tertiary amine to yield a crude solution of a compound of Formula 2; b) filtering the crude solution of compound of Formula 2 obtained in a) to remove solid amine hydrochloride, reacting the filtrate without isolation or further purification with a compound of Formula 3, and isolating 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid; c) reacting the 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid isolated in b) with tert-butylamine to yield a compound of formula 4; d) isolating and purifying the compound of formula 4; and e) converting the compound of formula 4 to a compound of formula 5. | 03-18-2010 |
20090281320 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE] BISPHOSPHONIC ACID AND HEMIPENTAHYDRATE MONOSODIUM SALT THEREOF - The invention relates to a novel process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof comprising (a) reacting an aqueous solution of 3-pyridyl acetic acid hydrochloride with phosphorus trichloride; (b) removing unreacted phosphorus trichloride; (c) adding water and hydrolyzing; (d) isolating crystalline [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid; (e) suspending said crystalline [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid in water; (f) adding sodium hydroxide, filtering off, and washing; and (g) drying obtained hemipentahydrate monosodium salt of 1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid. | 11-12-2009 |
20090005413 | Novel Salt of Montelukast - The invention relates to a novel salt of montelukast with tert-butylamine and its use in the process for the preparation of highly pure free montelukast acid and/or pharmaceutically acceptable salts thereof, in particular montelukast sodium. | 01-01-2009 |
20080242872 | AMORPHOUS CARVEDILOL PHOSPHATE AND METHOD OF MANUFACTURING THEREOF - The subject of the invention is amorphous carvedilol phosphate and a method of manufacturing amorphous carvedilol phosphate comprising removing solvent from carvedilol phosphate solution by means of spray drying. | 10-02-2008 |